Households in Britain with a user of GLP-1 drugs are spending £1bn ($1.31bn) less on grocery products, data suggests.
Research by Worldpanel by Numerator also indicates there are 2.6 million adults in Britain using the weight-loss medication.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The study, Worldpanel’s fourth, was carried out in August and took in more than 9,600 households.
A poll the researchers conducted in June estimated GLP-1 users were spending £780m less on groceries. The latest survey indicates the impact is now more than £1bn.
Chantel Kennaugh, head of public sector and nutrition at Worldpanel, said: “Too often, the GLP-1 impact is framed as a story about value or volume decline but there’s a much more interesting story sitting behind this. From a grocery perspective, this new audience is being more mindful about what and how they eat.”
The researchers said impulse and indulgence products had been most affected. The amount GLP-1 users spend on crisps has fallen 15%, the data shows. Expenditure on alcohol has fallen by the same amount.
Volume sales of frozen ready meals have jumped 30%, while unit sales of hot chocolate and malt drinks has grown 16%.
Worldpanel said some spending is being redirected to other sectors. The firm said GLP-1 users spent £78m more than expected on health and beauty products in the first year after they started taking the medication.
The researchers estimate 8.5% of households in Britain contain a GLP-1 user, which amounts to the number of vegetarians and pescatarians combined.
Kennaugh added: “Our estimates suggest that GLP-1 usage is set to surpass 10% of GB households in 2027. This is not a flash-in-the-pan trend but a seismic change that requires retailers and manufacturers to re-think their strategies.”
On the other side of the Atlantic, research by Tesco-owned customer data firm Dunnhumby has suggested GLP-1 drugs are influencing what more than one in five adults across the Americas eat and drink.
After surveying 8,500 consumers across six countries in August, Dunnhumby said each GLP-1 user shapes the dietary habits of an average of 2.08 people within their household.
Across the six markets in the Americas surveyed – the US, Canada, Mexico, Brazil, Colombia, and Chile – 10.2% of adults have used a GLP-1 medication, while 21.3% say their food and drink choices are shaped by the drugs.